title: Cationic liposomes with plasmid DNA influence cancer metastatic capability.
abstract: BACKGROUND
  Cancer gene therapy is now being developing to provide new strategies for the treatment of human tumors. Cationic lipids represent one of the powerful mediators for DNA delivery. The liposome-plasmid DNA complex itself is known to inhibit tumor cell growth, but other effects on cancer cell behaviors have not been reported so far.
  
  
  METHODS
  Six commercially available cationic liposomes complexed with plasmid DNA were applied to cancer cells and their metastatic potentials were measured.
  
  
  RESULTS
  The liposome-plasmid DNA complexes affected metastatic capability in three different ways: TM-TPS:DOPE and DOTAP:DOPE had no effect on metastatic capability; a suppressive effect was observed in DOSPA:DOPE and DMRIE:cholesterol; while an augmentative effect was observed in DOTMA:DOPE and Effectene. These effects are likely to be DNA sequence independent, because different plasmids have the same effects.
  
  
  CONCLUSIONS
  Liposome-plasmid DNA complexes influence cancer metastasis capability, dependent upon the cationic liposome formulations.
authors.affiliation: Division of Cancer Research, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan.
authors.forename: Takahide
authors.initials: T
authors.lastname: Ota
authors.forename: Masayo
authors.initials: M
authors.lastname: Maeda
authors.forename: Masaaki
authors.initials: M
authors.lastname: Tatsuka
mesh_terms: D016475:3T3 Cells; D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000556:secondary / Q000628:therapy; D002411:Cation Exchange Resins / Q000008:administration & dosage / Q000494:pharmacology; D002412:Cations; D002461:Cell Line, Transformed; D004247:DNA / Q000008:administration & dosage* / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D008055:Lipids / Q000008:administration & dosage / Q000494:pharmacology; D008081:Liposomes / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008546:Melanoma, Experimental / Q000556:secondary / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology; D010957:Plasmids / Q000008:administration & dosage* / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D002411:Cation Exchange Resins; D002412:Cations; D008055:Lipids; C086724:Lipofectamine; D008081:Liposomes; D010714:Phosphatidylethanolamines; C020888:1,2-dielaidoylphosphatidylethanolamine; D004247:DNA